Abstract
N/A
Highlights
Roflumilast cream, a phosphodiesterase-4 (PDE-4) inhibitor that is more potent than other PDE-4 inhibitors,[1] is under investigation as a once-daily, nonsteroidal, topical treatment for psoriasis
Baseline is defined as the last observation prior to the first dose of roflumilast cream in either the ARQ-151-201 or ARQ-151-202 study
Among all rollover groups, IGA success was between 33% and 37%, and exceeded that observed among these patients at Week 12 of the parent study
Summary
Topical treatment options for chronic plaque psoriasis lack products that are safe with long-term usage, are well tolerated, and are used as single agents over the entire body. Roflumilast cream, a phosphodiesterase-4 (PDE-4) inhibitor that is more potent than other PDE-4 inhibitors,[1] is under investigation as a once-daily, nonsteroidal, topical treatment for psoriasis. In a phase 2b randomized, double-blind, 12-week trial of 331 adults with chronic plaque psoriasis, roflumilast cream once daily was found to be superior to vehicle cream and was well tolerated[2]. This multicenter, open-label, 52-week study was conducted to assess long-term safety of roflumilast 0.3% cream in patients with chronic plaque psoriasis. ELIGIBILITY Diagnosis of at least mild plaque psoriasis for at least 6 months Age ≥18 years 2-25% BSA*.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.